Newborn Metabolic, Endocrine and Hemoglobinopathy and Newborn Hearing Loss Screening Programs Mandate
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Governs Rhode Island state-mandated coverage and reimbursement requirements for newborn metabolic, endocrine, hemoglobinopathy, and newborn hearing screening programs for insured newborns and responsible providers/facilities.
No material clinical or coverage changes in this revision.
Coverage Criteria and Mandates
Mandated Screening Coverage and Obligations
Covered as a mandated state benefit with specific provider and laboratory obligations
Religious exemption per R.I. Gen. Laws § 23-13-14 applies.
Confirmed diagnoses and associated data (diagnostic test type, treatment type, and other information requested by the Director) must be reported to the Department within 90 days of confirmation.
Laboratories performing newborn screening tests must be approved by the Director; program services are subject to the established fee schedule.
In absence of a third‑party payor or sufficient insurance information, hospitals or other birth facilities (and attending providers for out‑of‑facility births) must pay costs but may bill the patient; self‑funded groups may opt out and Medicare Advantage may not be subject to state mandates.
Mandated newborn screening coverage
Covered when ALL of the following statutory and program conditions are met:
Parents may object to hearing tests on religious grounds; such tests shall not be performed.
In the absence of a third‑party payor or sufficient insurance information, costs (including the coordination fee) shall be paid by the hospital or other health care facility where the birth occurred, or by attending clinicians for out‑of‑facility births; facilities/providers may bill the patient directly.
Code 84999-32 is the unlisted code used by the DOH laboratory for newborn metabolic screening.
The Rhode Island Newborn Screening Program is designated as a mandated state-covered benefit reimbursable by health insurers; however, applicability to some payer types is limited. Medicare Advantage plans are not subject to the State mandate unless specifically noted elsewhere in the policy, and self‑funded employer groups may elect not to follow state mandates. When the patient is eligible for Medical Assistance, the Rhode Island Department of Human Services will pay for the Newborn Screening Program. If no third‑party payer or sufficient insurance information exists, the hospital or birth facility — or the attending providers for out‑of‑facility births — are responsible for payment but may bill the patient directly.
Not all insurance products are required to reimburse the Newborn Screening Program. Supplemental policies that only provide coverage for specific diseases, hospital indemnity, Medicare supplement, or other supplemental policies are excluded from the state mandate to reimburse screening. Benefits also vary by contract; providers should confirm coverage in the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement because group‑level or contract exclusions (including some self‑funded plans) can result in non‑coverage.
Billing and Coding
| 84999-32 | Unlisted code used by DOH laboratory representing all newborn metabolic tests |
Provider Responsibilities, Billing, and Reporting
Reporting requirements — Laboratory and provider obligations
All reports of newborn screening tests performed by a laboratory must be submitted to the attending physician and to the Rhode Island Department of Health. Reports shall include the actual measured value and the reference ranges used for each disorder.
- Submit confirmed newborn screening diagnoses, diagnostic test type, treatment type, and any additional information required by the Director for surveillance or program needs.
- Confirmed cases and required data must be submitted to the Department's Newborn Screening Program within 90 days of confirmation.
Reporting and billing responsibility
The hospital or health care facility where the birth occurred is responsible for drawing and forwarding newborn screening specimens to the Department of Health Laboratory. If there is no third-party payor or sufficient insurance information for billing and collection, the costs for the Newborn Screening Program (including coordination fees) shall be paid by the hospital or facility; hospitals/facilities may bill the patient directly. The Rhode Island Department of Human Services will pay when the patient is eligible for Medical Assistance.
- Hospitals forward samples to DOH Laboratory for testing.
- DOH Laboratory submits claims under unlisted code 84999-32 representing all tests.
- In the absence of insurance or billing information, facility/provider bears program costs; DOH/DHS pays when patient is eligible for Medical Assistance.
Specimen collection materials
The Department shall provide filter specimen slips to health care facilities where births occur and to clinicians attending out-of-facility births. The slips include instructions for specimen collection and submission to the contracted laboratory.
- Use the State-provided filter specimen slips for collection and submission.
- Ensure specimens are collected per the instructions on the slips and forwarded to the Department-contracted laboratory.
Program scope and statutory requirements
Newborn hearing screening is statutorily required for all newborns in Rhode Island per R.I. Gen. Laws § 23-13-13 and related procedures, but parents may opt out on religious grounds. Labs performing newborn screening must be approved by the Director.
- Follow the "Procedures for Evaluating Newborn Infants for Hearing Impairments" available at www.health.ri.gov/programs/hearingassessment/.
- Obtain and maintain Director approval for laboratories performing mandated newborn screening tests.
Background and Purpose
Newborn screening aims to identify conditions not apparent at birth so early interventions can prevent death or irreversible disability. Rhode Island’s program screens for a broad panel of metabolic, endocrine, hemoglobinopathy and other disorders (for example, amino acid disorders, organic acid disorders, fatty acid oxidation disorders, hemoglobin traits and disorders, congenital hypothyroidism and congenital adrenal hyperplasia, lysosomal storage disorders, spinal muscular atrophy, biotinidase deficiency, cystic fibrosis, classical galactosemia, and severe combined immunodeficiency). In addition, hearing screening is required for all newborns under R.I. Gen. Laws § 23-13-13 (with a parental religious exemption permitted). Screening is typically performed in the first days of life using heel‑prick blood specimens and newborn hearing screens prior to discharge to enable prompt diagnostic follow‑up and treatment when indicated.
Definitions and Tested Conditions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.